Safety study of a new drug in healthy volunteers
Part of Lungs & breathing clinical trials.
This study tests a new investigational drug called SV001 in healthy volunteers to see if it is safe and how the body handles it. It is a first-in-human trial, meaning this drug has not been tested in people before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a healthy adult between 18 and 65 years old (implied by Chinese Healthy Adult Volunteers).
- Your weight must be at least 50 kg if male, or 45 kg if female, with a body mass index (BMI) between 19 and 26.
- You cannot have a history of serious drug allergies, drug abuse, or heavy smoking.
- You must not have any significant medical conditions or take other medications that could interfere with the study.
- You agree to use reliable birth control during and for a period after the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental pill called SYH2059 for people with IPF, a condition that causes lung scarring and makes breathing harder. The goal is to see if the pill is safe and can help slow down the disease.
This trial tests a new medicine, ORJ-001, for people with idiopathic pulmonary fibrosis (IPF), a lung condition that causes scarring. The goal is to see if it can help slow the disease and improve breathing.
This study tests a new oral medication in healthy men to see how the body absorbs, processes, and eliminates it. It's an early step to determine safety and dosing, and you would be closely monitored.
This trial tests a new drug called SRN001 in healthy men to see how safe it is and how the body processes it. It may help find the right dose for future studies.
This trial tests a new drug, SB17170, for people with IPF. It aims to see if the drug can help slow down lung damage. You may be eligible if you have a confirmed diagnosis of IPF and meet certain lung function criteria.
This study tests an inhaled medication for people with idiopathic pulmonary fibrosis (IPF), a lung condition that causes scarring. The goal is to see if the drug is safe and how it works in the body. It might help by targeting the lungs directly with fewer side effects.
Hear when a new Idiopathic Pulmonary Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.